12,372 trials
Dysfunctional Central Venous Access Catheters
Primary: Percentage of Patients Who Had Restoration of Central Venous Catheter (CVC) Function Following a Single Administration of Study Drug — 23.4; 60.0 percentage of…
Infections, Papillomavirus
Primary: Number of Seroconverted Subjects for Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibodies, in Women 15 to 25 Years of…
Constipation
Primary: Mean Number of Complete Spontaneous Bowel Movements (CSBMs) Per Week Over the 4 Weeks Treatment Period — 1.9; 5.2 CSBMs per week — p=<0.0001
Helicobacter Infections
Primary: Helicobacter Pylori Eradication Confirmed by Urea Breath Test — 166; 112 Participants
Tetanus · Acellular Pertussis · Diphtheria
Primary: Number of Subjects With Antibody Concentration Against Vaccine Antigens, Above a Protocol Defined Cut-off Value — 729; 374; 836; 428 subjects
Rheumatoid Arthritis
Primary: Percentage of Patients With an Improvement of at Least 50% in American College of Rheumatology (ACR) Score (ACR50) From Baseline at Week 24 — 30.1; 11.2 Percentage of…
Diabetes · Diabetes Mellitus, Type 2
Primary: Mean Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) at Week 26 — -1.24; -1.5; -0.9 Percentage point of total HbA1c — p=0.0001
Meningococcal Meningitis · Meningococcal Infections
Primary: Number of Subjects With at Least One Severe Systemic Reaction, Ages 19 to 55 Years — 95; 46 Subjects
Skin Infections, Bacterial
Primary: Number of Participants With Clinical Success and Failure at Follow-up (7-9 Days Post Therapy) for the Primary Efficacy Population — 184; 75; 62; 38 participants — p=0.098
Postmenopausal Osteoporosis
Primary: Percent Change From Baseline in Total Hip Bone Mineral Density — 1.05; 1.9 Percent Change — p=<0.0001
Asthma
Primary: Number of Patients With Clinical Adverse Experiences (CAE) Reported by Patients - Base Study — 202; 406; 26; 55 Participants
Lymphoma, Non-Hodgkin
Primary: Event-free Survival (EFS) — 9; NA Months
Heart Failure
Primary: Number of Participants That Experienced One Component of the Composite Clinical Endpoint of All Cause Death or Hospitalization for Heart Failure — 889; 828 Participants…
Carcinoma, Renal Cell
Primary: Progression-free Survival — 9.2; 4.2 months — p=.0000001
Thrombosis, Venous
Primary: Number of Participants With at Least on Event of Venous Thromboembolism (VTE) and/or Death From Any Cause Recorded up to Day 47 — 13; 88 participants — p=<0.001